News

Novelwise Pharmaceuticals Announces Collaboration with U.S. Patient Advocacy Group A Cure In Sight (ACIS) to Advance Ocular Melanoma Research
 2025/08/25

Novelwise Pharmaceuticals Announces Collaboration with U.S. Patient Advocacy Group A Cure In Sight (ACIS) to Advance Ocular Melanoma Research

Novelwise Pharmaceuticals is honored to announce its collaboration with the U.S. patient advocacy organization A Cure In Sight (ACIS) in August 2025.

Novelwise Pharmaceuticals Announces FDA “May Proceed” Clearance for Phase Ib/II Trial of NBM-BMX in Metastatic Uveal Melanoma
 2025/07/30

Novelwise Pharmaceuticals Announces FDA “May Proceed” Clearance for Phase Ib/II Trial of NBM-BMX in Metastatic Uveal Melanoma

Taipei, July 30, 2025 —— Novelwise Pharmaceuticals today announced that its investigational cancer therapy NBM-BMX has been deemed may  proceed by the United States Food and Drug Administration (US FDA).